How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma
Review Konstantinos Arvanitakis 1,2 , Theocharis Koufakis 3 , Kalliopi Kotsa 3 and Georgios Germanidis 1,2 1 First Department of Internal Medicine, AHEPA University Hospital,